Inspire Medical Systems Inc expected to post a loss of 65 cents a share - Earnings Preview

Inspire Medical Systems

03/05/2024 23:14

* Inspire Medical Systems Inc  INSP.N   INSP.K  is expected
to show a rise in quarterly revenue when it reports  results on
May 7 for the period ending March 31 2024
    * The Golden Valley Minnesota-based  company is expected to
report
a 26.2% increase in revenue to $161.438 million from $127.9
million a year ago, according to the mean estimate from 17
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Inspire Medical Systems
Inc is
for a loss of 65 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 6
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 10.0%
in the last three months. ​
    * Wall Street's median 12-month price target for Inspire
Medical
Systems Inc is $265.00​, above​ its last closing price
of $249.72. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.03       -0.09      0.49      Beat    653.2
 Sep. 30 2023  -0.53       -0.58      -0.29     Beat    50
 Jun. 30 2023  -0.54       -0.57      -0.41     Beat    28​
 Mar. 31 2023  -0.67       -0.66      -0.53     Beat    19.7
 ​​Dec.        -0.48       -0.57      0.10      Beat    117.7
 31 2022                                                
 Sep. 30 2022  -0.74       -0.77      -0.60     Beat    21.7​
 Jun. 30 2022  -0.61       -0.62      -0.53     Beat    14.3
 Mar. 31 2022  -0.75       -0.80      -0.61     Beat    23.4
 This summary was machine generated May 3 at 22:14 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)